CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study - Pariser, David M.; Lebwohl, Mark G.; Jaworski, Janusz; Trefler, Jakub; Daniluk, Stefan; Dudek, Anna; Baran, Wojciech; Owczarek, Witold; Brzewski, Pawel; Sikora, Mariusz; Krogulec, Marek; Kim, SungHyun; et al. (Dermatology and therapy, 2025)
Keywords: Adalimumab; Biological products; Biosimilar; CT-P17; Dermatology; Drug therapy; Interchangeability; Internal Medicine; Medicine; Medicine & Public Health; Oral and Maxillofacial Surgery; Original Research; Pharmacokinetics; Plastic Surgery; Psoriasis; Quality of Life Research; Switching; Testing; Poland; CT-P17; Psoriasis; Tumor necrosis factor inhibitor; Yuflyma; Adalimumab; Interchangeability; TNF; Biosimilar; Switching